Loading patent…
AssigneesCentre National De La Recherche Scientifique, Universite De Montpellier 2
InventorsJean-Luc Georges Laurent Battini, Nicolas Gabriel Albert Manel, Felix Jinhyun Kim, Sandrina Kinet, Naomi Taylor, Marc Sitbon
Estimating the term…
The invention relates to the use of the ubiquitous vertebrate glucose transporter GLUT1, or of fragments or sequences derived thereof, for the in vitro diagnosis of cancers, when used as a tumor marker, or for the screening of compounds useful for the preparation of drugs for the prevention or the treatment of pathologies linked to an infection of an individual with a PTLV, or pathologies linked to an overexpression of GLUT1 on cell surfaces, or the in vitro detection of GLUT1 on cell surfaces. The invention also relates to pharmaceutical compositions containing GLUT1, or fragments or sequences derived thereof, and to their uses such as in the frame of the prevention or the treatment of pathologies linked to an infection of an individual with a PTLV.
A method for treating solid tumors overexpressing GLUT1 on cell surfaces, said method comprising administering to a subject in need thereof an effective amount of a GLUT1 binding polypeptide,
A method of inhibiting glucose consumption in breast cancer tumor cells in a patient, comprising administering to the patient an effective amount of a GLUT1 binding polypeptide, said GLUT1 binding polypeptide comprising the polypeptide selected from the group consisting of:
A method of treating breast cancer, comprising administering to a patient in need thereof an effective amount of the polypeptide selected from the group consisting of:
Dependencies are inferred from the claim text.